Beta Bionics CMO sells 4,221 shares for taxes

Beta Bionics’ Chief Medical Officer sold shares mainly to cover tax withholding from RSU vesting, retaining a substantial direct holding afterward.

Rhea-AI Filing Summary

Beta Bionics, Inc. (BBNX) reported that Chief Medical Officer Steven Jon Russell sold 4,221 shares of common stock on September 2, 2026. The filing states these shares were sold to cover tax withholding obligations related to the vesting of restricted stock units, and not as a discretionary sale of investment holdings.

The weighted average sale price was $19.1131 per share, within a reported range of $18.89 to $19.545. After this transaction, Russell held 169,628 shares of Beta Bionics common stock directly. No transactions were reported under a Rule 10b5-1 trading plan.

Insider Trade Summary

Net Seller: 4,221 shares

Net Sell 1 txn

Insider Russell Steven Jon

Role Chief Medical Officer

Sold 4,221 shs ($81K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1, F2	4,221	$19.1131	$81K

Holdings After Transaction: Common Stock — 169,628 shares (Direct)

Footnotes (2)

1. F1. The shares were sold to cover tax withholding obligations associated with the vesting of restricted stock units.
2. F2. The weighted average sale price for the transaction reported was $19.1131 and the range of prices were between $18.89 and $19.545. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

Key Figures

Shares sold: 4,221 shares Weighted average sale price: $19.1131 per share Price range for sales: $18.89 to $19.545 per share +1 more

4 metrics

Shares sold 4,221 shares Common stock sold on September 2, 2026

Weighted average sale price $19.1131 per share Sale of 4,221 shares on September 2, 2026

Price range for sales $18.89 to $19.545 per share Range of prices for the reported sale transaction

Shares held after transaction 169,628 shares Direct common stock ownership of CMO after sale

Key Terms

restricted stock units, weighted average sale price, tax withholding obligations

3 terms

restricted stock units financial

"tax withholding obligations associated with the vesting of restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

weighted average sale price financial

"The weighted average sale price for the transaction reported was $19.1131"

tax withholding obligations financial

"shares were sold to cover tax withholding obligations associated with the vesting"

FAQ

What insider transaction did Beta Bionics (BBNX) report for its Chief Medical Officer?

Beta Bionics reported that Chief Medical Officer Steven Jon Russell sold 4,221 shares of common stock on September 2, 2026. The filing explains the sale was to cover tax withholding obligations from vesting restricted stock units, rather than a discretionary reduction of investment holdings.

How many BBNX shares did the Chief Medical Officer sell and at what price?

The Chief Medical Officer sold 4,221 shares of Beta Bionics common stock at a weighted average price of $19.1131 per share. The filing notes the trade prices ranged between $18.89 and $19.545, and detailed breakdowns are available upon request to the issuer or the SEC staff.

Why did the Beta Bionics (BBNX) Chief Medical Officer sell shares?

According to the filing, the shares were sold to cover tax withholding obligations associated with the vesting of restricted stock units. This indicates the transaction was tied to equity compensation vesting mechanics rather than a discretionary open-market decision to reduce ownership.

How many BBNX shares does the Chief Medical Officer hold after this transaction?

After the September 2, 2026 transaction, Chief Medical Officer Steven Jon Russell held 169,628 shares of Beta Bionics common stock directly. The Form 4 does not report any derivative securities positions, focusing solely on this non-derivative stock sale.

Was the Beta Bionics (BBNX) insider sale made under a Rule 10b5-1 plan?

The filing indicates that the Rule 10b5-1 checkbox is not affirmed and the footnotes do not reference a trading plan. Based on this disclosure, the reported sale to cover tax withholding was not described as being made under a Rule 10b5-1 trading arrangement.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/03/2026 - 06:20 PM Accepted by SEC EDGAR 09/03/2026 - 06:15 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Russell Steven Jon

(Last) (First) (Middle)

C/O BETA BIONICS, INC.

11 HUGHES

(Street)

IRVINE CALIFORNIA 92618

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Beta Bionics, Inc. [ BBNX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/02/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/02/2026		S(1)		4,221	D	$19.1131(2)	169,628	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The shares were sold to cover tax withholding obligations associated with the vesting of restricted stock units.

2. The weighted average sale price for the transaction reported was $19.1131 and the range of prices were between $18.89 and $19.545. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

	/s/ Stephen Feider, Attorney-in-Fact	09/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)